NLS Pharmaceutics Ltd Stock

$1.80

1.10% today

Nasdaq, Feb 28, 05:02 pm CET

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

NLS Pharmaceutics Ltd Stock price

$1.82

-113.78 98.43% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

+0.03 1.39%

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$4.50m
Enterprise Value	$5.66m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-6.31m
EPS (TTM) EPS	$-0.19
P/E forward	negative
Short interest	4.45%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

NLS Pharmaceutics Ltd Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

1x Hold

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

Hold

100%

Analyst Estimates with Stock Price Targets

Financial data from NLS Pharmaceutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.01 0.01	0% 0% -
Gross Profit	-0.01 -0.01	0% 0% -
- Selling and Administrative Expenses	4.49 4.49	31% 31% -
- Research and Development Expense	1.80 1.80	77% 77% -
EBITDA	-6.30 -6.30	56% 56% -
- Depreciation and Amortization	0.01 0.01	0% 0% -
EBIT (Operating Income) EBIT	-6.31 -6.31	56% 56% -
Net Profit	-6.60 -6.60	57% 57% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

NLS Pharmaceutics Ltd Stock News

Neutral

PRNewsWire

●

one day ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

ZÜRICH, Switzerland , Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon Labs Inc. ("Aexon Labs"), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist ("DOXA") for narcolepsy and related neurological disorders.

Neutral

PRNewsWire

●

3 days ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel , Feb. 25, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd.

Neutral

PRNewsWire

●

18 days ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to transform diabetes care. Diabetes more than just a Metabolic Disorder: Diabetes is a multi-systemic disease impacting the central nervous system (CNS), immune function, and cellular metabolism.

More NLS Pharmaceutics Ltd News

Company Profile

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder(ADHD). The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.

Head office	Switzerland
CEO	Alexander Zwyer
Employees	4
Founded	2015
Website	www.nlspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now